Continuous intravenous infusion of recombinant human endostatin using infusion pump plus chemotherapy in non-small cell lung cancer

doi:10.12998/wjcc.v10.i4.1164

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 4

This Article

Academic Content and Language Evaluation of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3295)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-3) series.

Item

Count

PDF

215

WORD

186

HTML

1494

Figures (1-1)

205

Tables (1-3)

201

Sum=2301

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

337

Download

657

Sum=994

Feb 6, 2022 (publication date) through May 19, 2024

Times Cited of This Article

Times Cited (3)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Feb 6, 2022; 10(4): 1164-1171
Published online Feb 6, 2022. doi: 10.12998/wjcc.v10.i4.1164

Table 2 Relationships between clinicopathological features and short-term efficacy

Clinicopathological features	Case	CR	PR	SD	PD	ORR	CBR	P value
Pathological type								0.848
Squamous cell carcinoma	10	0	2	6	2	20.0%	80.0%
Adenocarcinoma	35	0	8	22	5	22.9%	85.7%
Chemotherapy regimen								0.411
Dual-drug chemotherapy + Rh-endostain	18	0	5	11	2	27.8%	88.9%
Single-drug chemotherapy + Rh-endostain	27	0	5	17	5	18.5%	81.5%

ORR: Objective response rate; CBR: Clinical benefit rate; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressed disease.

Citation: Qin ZQ, Yang SF, Chen Y, Hong CJ, Zhao TW, Yuan GR, Yang L, Gao L, Wang X, Lu LQ. Continuous intravenous infusion of recombinant human endostatin using infusion pump plus chemotherapy in non-small cell lung cancer. World J Clin Cases 2022; 10(4): 1164-1171
URL: https://www.wjgnet.com/2307-8960/full/v10/i4/1164.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i4.1164